Compression-Coated Microparticles Show Promise for Targeted GHK-Cu2+ Delivery to the Colon
Background
Inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis often require targeted drug delivery to the colon to maximize therapeutic effect and minimize systemic side effects. The peptide glycyl-L-histidyl-L-lysine-Cu(II) (GHK-Cu2+) is known for its anti-inflammatory and tissue-regenerating properties, making it a promising candidate for treating colonic inflammation. However, its degradation in the upper gastrointestinal tract limits its efficacy; developing a delivery system that protects GHK-Cu2+ until it reaches the colon is a critical unmet need.
Results
The in vitro evaluation demonstrated a highly controlled release profile for the GHK-Cu2+-loaded microparticles. In simulated gastric fluid (pH 1.2), there was minimal drug release, indicating excellent protection from stomach acidity. Similarly, in simulated small intestinal fluid (pH 6.8), the microparticles maintained their integrity with negligible GHK-Cu2+ release, preventing premature degradation. The most significant finding was the high and sustained release of GHK-Cu2+ specifically in simulated colonic fluid (pH 7.4), confirming the successful design for targeted delivery. This selective release mechanism suggests that the compression coating effectively protected the peptide until it reached the desired site of action in the colon.
Why It Matters
This study successfully demonstrates a novel formulation strategy for GHK-Cu2+ that could significantly improve its therapeutic potential for colonic conditions. Targeted delivery to the colon could enhance local efficacy while reducing systemic exposure and potential side effects, a major advantage for chronic conditions like IBD. This in vitro success lays the groundwork for future in vivo animal studies and potentially human clinical trials, paving the way for a new treatment option for inflammatory bowel diseases. The technology could also be adapted for other sensitive therapeutic peptides or drugs requiring site-specific release in the lower GI tract.